Arovella licenses novel CAR-iNKT cell armouring technology: Media coverage

ArovellaTherapeutics Ltd is pleased to announce it has entered into a global, exclusive license with University of North Carolina Lineberger Comprehensive Cancer Center to incorporate a novel armouring cytokine technology (IL-12-TM) for its CAR-iNKT cell platform.

Media received following the announcement:

Stockhead: ASX Health Stocks: A breakthrough for CAR T therapy? Arovella signs deal to advance CAR-iNKT platform

Herald Sun: ASX Health Stocks: CAR T therapy breakthrough? Arovella signs deal to advance CAR-iNKT platform

Adelaide Now: ASX Health Stocks: CAR T therapy breakthrough? Arovella signs deal to advance CAR-iNKT platform

Geelong Advertiser: ASX Health Stocks: CAR T therapy breakthrough? Arovella signs deal to advance CAR-iNKT platform

Daily Telegraph: ASX Health Stocks: CAR T therapy breakthrough? Arovella signs deal to advance CAR-iNKT platform

The Mercury: ASX Health Stocks: CAR T therapy breakthrough? Arovella signs deal to advance CAR-iNKT platform

NT News: ASX Health Stocks: CAR T therapy breakthrough? Arovella signs deal to advance CAR-iNKT platform

BiotechDispatch: Arovella licences novel CARiNKT cell armouring technology